Journal profile · Multiple
Osteoporosis and Sarcopenia
ISSN 2405-5255 · eISSN 2405-5263 · Elsevier · Korea, Republic of
Osteoporosis and Sarcopenia: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.4 (journal website); diamond open access (no APC); no APC; median 67 days to acceptance (47 articles, last 24 months); 88 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Osteoporosis and Sarcopenia is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Bone health and osteoporosis research, Hip and Femur Fractures and Nutrition and Health in Aging, together about 43% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Osteoporosis and Sarcopenia is the official, peer-reviewed open-access journal of the Asian Federation of Osteoporosis Societies (AFOS). The journal aims to further research in the areas of osteoporosis, fracture, sarcopenia, frailty, metabolic bone diseases, mineral metabolism, as well as biology, physiology, and pathology of bone and muscle with a specific focus on Asian uniqueness in genetic, ethnic, social, and environmental differences. Despite the journal's Asian focus, we welcome appropriate submissions from all over the world.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Yoon-Sok ChungPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named South Korea 21, Taiwan, China 6, Japan 6, United States 4, United Kingdom 2 (51 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Bone health and osteoporosis researchMedicine24.1%
- Hip and Femur FracturesMedicine10.5%
- Nutrition and Health in AgingMedicine8.4%
- Bone health and treatmentsMedicine7.7%
- Bone Metabolism and DiseasesBiochemistry, Genetics and Molecular Biology6.3%
- Vitamin D Research StudiesMedicine4%
- Bone and Joint DiseasesMedicine4%
- Body Composition Measurement TechniquesMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
| Minor | Orthopedics | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
| Minor | Orthopedics | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
ScopusPubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 2.4Publisher website ·
- h-index
- 33OpenAlex ·
- i10-index
- 147OpenAlex ·
- 2-year mean citedness
- 1.95OpenAlex ·
- Self-citation rate
- 12.5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 28LetPub ·
Articles by year OpenAlex count · 727 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 24 | 24 | 9 |
| 2025 | 88 | 88 | 173 |
| 2024 | 34 | 34 | 103 |
| 2023 | 75 | 75 | 186 |
| 2022 | 29 | 29 | 269 |
| 2021 | 38 | 38 | 602 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
67 daysMedian, submission to acceptance · P25–P75 47 days – 97 days
- Acceptance to online
- median 14 days (47 articles)
- Submission to online
- median 84 days
- Sample
- 47 articles with submission and acceptance dates (51 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 20 weeksLetPub ·
- First decision after review
- 40 daysPublisher website ·
- Submission to acceptance
- 66 daysPublisher website ·
- Acceptance to publication
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 20 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 500 | — | — | |
| LetPub | No APC | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Manuscript length
- ≤ 5,000 words
- Reference style
- Vancouver
- First submission
- Free format: the journal's layout is not required
- Cover letter
- Required
Article types accepted9, with length limits
- case report**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…main text ≤ 2,000 words
- editorial**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- letter**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- letter to the editor**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- letters to the editor**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- opinion**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- original article**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- perspective**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
- review**Editorial:**These are manuscripts that are related to materials within an issue; they raise challenging questions or expose controversies. The editor solicits…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Author contributions
For transparency, we encourage corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor's specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administratio…
Source ↗Publisher website ·- Conflicts of interest Conflict of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also https://www.elsevier.com/conflictsofint…
Source ↗Publisher website ·- Data availability Data sharing statements for clinical trials
Data sharing statements for clinical trials Model summary
Clinical trials that begin enrolling participants on or after 1 January 2019 must include a data sharing plan in the trial's registration. The International Committee of Medical Journal Editors (ICMJE)'s policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html#two. If the data sharing plan chan…
Source ↗Publisher website ·- License & copyright Copyright Information
Submission of a manuscript implies:o that the work described has not been previously published (except in the form of an abstract);o that it is not under consideration for publication elsewhere;o that it has been approved by all co-authors, if any, as well as by the responsible authorities at the institute where the work was carried out;o that, if and when the manuscript is accepted for publicatio…
Source ↗Publisher website ·- Open access Open Access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two independent expert reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accept…
Source ↗Publisher website ·- Preprints Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the nam…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Korea, Republic of
- Language
- English
- ISSN
- 2405-5255
- Electronic ISSN
- 2405-5263
- Society / sponsor
- AFOS’ and ‘An Official Journal of the Korean Society of Osteoporosis
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Osteoporosis and Sarcopenia
What CAS zone is Osteoporosis and Sarcopenia in?
In the 2025 upgraded edition of the CAS Journal Ranking, Osteoporosis and Sarcopenia is in Zone 4 of Medicine, and in Zone 4 of the minor category Endocrinology & Metabolism / Orthopedics. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Osteoporosis and Sarcopenia?
The journal's website gives an impact factor of 2.4; this is the journal's own figure, as LetPub lists none for it; h-index 33.
How long does peer review take at Osteoporosis and Sarcopenia?
Based on the dates recorded on 47 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 67 days (interquartile range 47–97 days); authors report an average review time of about 20 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Osteoporosis and Sarcopenia?
According to the journal's author guidelines: Abstract: ≤ 250 words; Manuscript length: ≤ 5,000 words; Reference style: Vancouver; First submission: Free format: the journal's layout is not required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Osteoporosis and Sarcopenia based?
Of the 51 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are South Korea (21), Taiwan, China (6) and Japan (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Osteoporosis and Sarcopenia?
According to LetPub and DOAJ records, Osteoporosis and Sarcopenia is indexed in ESCI and DOAJ. The journal's website also lists Scopus and PubMed; that list has not been checked against each database.
Is Osteoporosis and Sarcopenia open access, and what is the APC?
Osteoporosis and Sarcopenia is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .